Loomis Sayles & Co. L P lifted its position in shares of NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 48.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,791,792 shares of the medical research company's stock after purchasing an additional 584,502 shares during the quarter. Loomis Sayles & Co. L P owned 1.40% of NeoGenomics worth $29,528,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Bellevue Group AG boosted its stake in shares of NeoGenomics by 34.2% during the 3rd quarter. Bellevue Group AG now owns 1,612,612 shares of the medical research company's stock worth $23,786,000 after buying an additional 410,516 shares during the last quarter. Jennison Associates LLC lifted its position in NeoGenomics by 18.7% during the fourth quarter. Jennison Associates LLC now owns 1,514,756 shares of the medical research company's stock worth $24,963,000 after acquiring an additional 238,288 shares during the last quarter. Segall Bryant & Hamill LLC boosted its holdings in shares of NeoGenomics by 11.6% during the fourth quarter. Segall Bryant & Hamill LLC now owns 2,113,822 shares of the medical research company's stock worth $34,836,000 after acquiring an additional 220,415 shares during the period. Vanguard Group Inc. boosted its stake in NeoGenomics by 1.4% in the 4th quarter. Vanguard Group Inc. now owns 14,239,887 shares of the medical research company's stock valued at $234,673,000 after purchasing an additional 195,793 shares during the period. Finally, State Street Corp grew its stake in shares of NeoGenomics by 1.6% in the third quarter. State Street Corp now owns 4,958,582 shares of the medical research company's stock valued at $73,139,000 after acquiring an additional 80,449 shares in the last quarter. Institutional investors and hedge funds own 98.50% of the company's stock.
NeoGenomics Price Performance
Shares of NeoGenomics stock traded up $0.09 during trading hours on Tuesday, reaching $9.58. The company's stock had a trading volume of 166,685 shares, compared to its average volume of 879,116. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.98 and a quick ratio of 1.91. NeoGenomics, Inc. has a one year low of $8.98 and a one year high of $19.12. The stock has a market cap of $1.23 billion, a P/E ratio of -15.36 and a beta of 1.28. The firm has a 50 day moving average price of $11.83 and a 200-day moving average price of $14.30.
NeoGenomics (NASDAQ:NEO - Get Free Report) last issued its quarterly earnings data on Tuesday, February 18th. The medical research company reported ($0.02) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.05). NeoGenomics had a negative net margin of 11.92% and a negative return on equity of 2.10%. The business had revenue of $172.00 million for the quarter, compared to analysts' expectations of $173.40 million. On average, analysts predict that NeoGenomics, Inc. will post -0.2 EPS for the current year.
Wall Street Analyst Weigh In
NEO has been the subject of several recent analyst reports. Bank of America cut their price objective on shares of NeoGenomics from $19.00 to $16.00 and set a "neutral" rating for the company in a research report on Wednesday, February 19th. The Goldman Sachs Group lowered their price objective on NeoGenomics from $20.00 to $18.00 and set a "buy" rating for the company in a research report on Tuesday, January 28th. Benchmark downgraded NeoGenomics from a "buy" rating to a "hold" rating in a research note on Monday, January 13th. Jefferies Financial Group initiated coverage on shares of NeoGenomics in a report on Tuesday, December 10th. They issued a "buy" rating and a $22.00 price target on the stock. Finally, Piper Sandler reduced their target price on NeoGenomics from $21.00 to $18.00 and set an "overweight" rating for the company in a research report on Wednesday, February 26th. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company's stock. According to MarketBeat.com, NeoGenomics has a consensus rating of "Moderate Buy" and a consensus target price of $19.60.
Read Our Latest Analysis on NEO
About NeoGenomics
(
Free Report)
NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.
Featured Stories
Before you consider NeoGenomics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NeoGenomics wasn't on the list.
While NeoGenomics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
